Wall Street Zen Upgrades Obsidian Therapeutics (NASDAQ:OBX) to Hold

Obsidian Therapeutics (NASDAQ:OBX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

OBX has been the topic of a number of other research reports. Piper Sandler initiated coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 target price on the stock. TD Cowen began coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They issued a “buy” rating for the company. Lifesci Capital began coverage on shares of Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. William Blair initiated coverage on shares of Obsidian Therapeutics in a research report on Wednesday, September 9th. They set an “outperform” rating for the company. Finally, Leerink Partners began coverage on shares of Obsidian Therapeutics in a research note on Tuesday, September 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Obsidian Therapeutics Trading Up 4.0%

NASDAQ OBX opened at $13.37 on Friday. Obsidian Therapeutics has a twelve month low of $12.16 and a twelve month high of $49.97.

About Obsidian Therapeutics

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.